Senti Biosciences (SNTI) Accumulated Expenses (2021 - 2022)
Senti Biosciences' quarterly Accumulated Expenses came in at $4.0 million in Q1 2022, up 396732.4% year-on-year from N/an in Q1 2021, and up 28.89% quarter-over-quarter from $3.1 million in Q4 2021.
Senti Biosciences has reported Accumulated Expenses for 2 years, with the latest figure at $4.0 million in Q1 2022.
- For the quarter ending Q1 2022, Accumulated Expenses rose 396732.4% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2022 stood at $4.0 million (up 396732.4% YoY), and the FY2021 full-year result was $3.1 million, changed N/A from the prior year.
- Accumulated Expenses for Q1 2022 stood at $4.0 million, up from $3.1 million in the prior quarter.
- The five-year high for Accumulated Expenses was $4.0 million in Q1 2022, with the low at $1000.0 in Q1 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 3.97 Mn |
| Dec 31, 2021 | 3.08 Mn |
| Sep 30, 2021 | 33,412.00 |
| Jun 30, 2021 | 2,347.00 |
| Mar 31, 2021 | 1,000.00 |